QuantHealth, an AI-driven clinical trial design firm, has successfully simulated over 100 trials, achieving 85% accuracy and notable returns on investment for pharmaceutical partners. By utilizing its proprietary technology and patient-focused solutions, the company tackles the common issue of trial failures. Traditionally, 90% of clinical trials fail due to poor protocol design, inefficiencies, and safety concerns, with drug development costing up to $1 billion and taking 10 to 15 years. QuantHealth’s Clinical-Simulator predicts individual patient responses, allowing design teams to better anticipate trial outcomes and refine their strategies.
In collaboration with a pharmaceutical company’s respiratory disease team, QuantHealth achieved cost savings exceeding $215 million and significantly boosted trial success rates. Using data from 350 million patients and 700,000 drug entities, QuantHealth’s advanced analytics module rapidly simulated over 5,000 protocol variations to pinpoint the most successful factors. Among 30 promising protocols, the best option was selected, cutting study duration by 11 months, reducing clinical trial subjects by 251, and lowering full-time employees needed by 1.5. This resulted in financial returns of $15 million, $200 million, and $385,000, respectively.
Orr Inbar, CEO and Co-Founder of QuantHealth, remarked, “It’s incredible to see the progress in AI-driven clinical trials over the past decade. What was once considered science fiction is now a reality, proving our technology’s ability to safely and accurately forecast trial outcomes. We currently work with five of the top 20 pharmaceutical companies, and we expect this number to double by next year. We are committed to tackling trial failures at scale and meeting market needs efficiently.”
QuantHealth’s outcomes in accuracy surpassed national averages for Phase II and III trials:
- Oncology: 88% accuracy, 58.3% better than the national rate of 29.7%
- Immune & Inflammation: 80% accuracy, 37.8% better than the national rate of 42.2%
- Gastroenterology: 83% accuracy, 41.4% better than the national rate of 41.6%
- Respiratory: 84% accuracy, 52.6% better than the national rate of 31.4%
For trial phases:
- Phase II: 88% accuracy, 59.1% better than the national rate of 28.9%
- Phase III: 83.2% accuracy, 25.4% better than the national rate of 57.8%
QuantHealth’s Clinical-Simulator undergoes rigorous validation, including logical, mathematical, clinical, and real-world assessments. It supports the entire trial development process, from target identification to regulatory approval. By collaborating closely with clients throughout the clinical trial journey, QuantHealth helps design teams anticipate trial dynamics, enhancing outcomes and minimizing setbacks.
About QuantHealth:
With 90% of drugs failing during the clinical stage, leading to a $45 billion annual waste, QuantHealth aims to address this issue by predicting patient responses in clinical trials. Leveraging a novel AI engine and extensive data, QuantHealth’s simulator provides high-accuracy predictions for trial outcomes, optimizing decisions on trial continuation, cohort selection, and drug repurposing. Founded by experts from top companies in the US and Israel, and supported by life-science investors and an advisory board of leading physicians and scientists, QuantHealth is at the forefront of revolutionizing clinical trials.
